Rendement sur 1 an (CAGR)
-6.19%
Sanofi SA Exchange (PA, EUR)
SAN.PA
74.05
+0.91 (+1.22%)
HealthcareDrug Manufacturers - General
Loading...
Rendement sur 3 ans (CAGR)
-9.48%
Rendement sur 5 ans (CAGR)
-2.03%
Rendement sur 10 ans (CAGR)
-0.17%
Analyse boursière d'Objective Corporation – État au sein de l'État
Lire plusCapitalisation boursière
90.17B
Cours/chiffre d'affaires
1.88
Valeur d'entreprise
143.31B
Cours/valeur comptable
1.30
Rendement du div
0.00%
Années de croissance
-
Croissance du div
-
Versement FCF
62.02%
Trailing P/E
13.34
PEG
-
P/E prévisionnel
8.30
Croissance EPS
-8.21%
Informations sur les actions
Qu'est-ce qu'une bourse ? Fonctionnement, acteurs, exemples
Lire plusGraphique boursier
Loading...
Données du prix des actions
| Ouverture | 74.74 |
| Max journalier | 75.26 |
| Min journalier | 74.32 |
| Volume journalier | 1.78M |
| Niveau record | 109.62 |
| Estimation des analystes sur 1 an | 94.28 |
| Beta | 0.28 |
| EPS (TTM) | 5.65 |
| Dividende par action | 0.00 |
| Date ex-div | 5 May 2026 |
| Prochaine date de bénéfices | 23 Apr 2026 |
Potentiel de baisse
Loading...
Données du potentiel de baisse
| SAN.PA | S&P500 | |
| Baisse de prix actuelle par rapport au niveau record | -32.45% | -2.08% |
| Baisse de prix actuelle la plus importante | -55.80% | -56.47% |
| Date de la baisse la plus importante | 10 Oct 2008 | 9 Mar 2009 |
| Baisse moyenne par rapport au record | -19.74% | -10.68% |
| Délai moyen pour nouveau record | 44 days | 12 days |
| Délai max pour nouveau record | 2908 days | 1805 days |
Actualite
Sanofi (NASDAQ:SNY) is prioritizing continued growth in Specialty Care while preparing for the loss of exclusivity of Dupixent in the early part of the next decade, according to Manuela Buxo, the comp...
20 septembre 2026
Investing.com -- European assets may offer investors advantages that are being overlooked as markets remain heavily focused on U.S. technology leadership, according to Macquarie Global Strategy, which...
20 septembre 2026
Corbus Pharmaceuticals' positive obesity data boosts its cannabinoid strategy, while CRB-701 and cash needs add key context for investors.
17 septembre 2026
COPENHAGEN, Denmark, September 17, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that Tarja Stenvall has been appointed President and Chief Executive Officer, effective October 15, 2026, succ...
17 septembre 2026
Healthcare stocks were slightly lower late Wednesday afternoon, with the NYSE Healthcare Index fract
16 septembre 2026
Sanofi today inaugurated the Charles Best Building, a flu vaccine manufacturing facility that will manufacture Sanofi's Fluzone® High-Dose influenza vaccine. This new manufacturing facility also offer...
16 septembre 2026
Earlier this month, Novavax participated in investor-focused healthcare conferences hosted by Citigroup and Cantor Fitzgerald in New York, outlining its vaccine and partnership positioning to a broad ...
16 septembre 2026
Sanofi has delivered mixed returns over recent years, and with the share price around €75.43, the real issue for you is whether that level is justified by the earnings power the group is producing tod...
15 septembre 2026
Cheplapharm has entered into a strategic partnership to take over a portfolio of 20 mature medicines along with three manufacturing facilities globally from Sanofi.
15 septembre 2026
Experienced life sciences executive brings more than two decades of global drug development, commercialization and business development experience SINGAPORE, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Humming...
15 septembre 2026